Results 171 to 180 of about 5,151 (200)

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Journal of Clinical Oncology, 2008
Brian I Rini, Susan Halabi
exaly  

The ALFA-tag is a highly versatile tool for nanobody-based bioscience applications

Nature Communications, 2019
Hansjörg Götzke, Markel Martínez-Carranza, Shama Sograte-Idrissi   +2 more
exaly  

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2014
Michael Manns, Maria Buti, Ewa Janczewska   +2 more
exaly  

Darbepoetin Alfa

2021
openaire   +1 more source

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

New England Journal of Medicine, 2007
Robert J Motzer, Thomas E Hutson, Stephane Oudard   +2 more
exaly  

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Lancet, The, 2008
Mario Santinami, Alessandro A E Testori, Reinhard Dummer   +2 more
exaly  

Darbepoetin-alfa

Reactions Weekly, 2019
openaire   +1 more source

High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801

Journal of Clinical Oncology, 2001
Joseph G Ibrahim, Vernon K Sondak
exaly  

Daprodustat/darbepoetin-alfa/roxadustat

Reactions Weekly, 2023
openaire   +1 more source

Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study

Journal of Clinical Oncology, 2005
Vladimir Semiglazov, Tadeusz Pienkowski
exaly